Department of Gynecologic Oncology, IRCCS National Cancer Institute, Milan, Italy.
Ann Surg Oncol. 2011 Nov;18(12):3469-78. doi: 10.1245/s10434-011-1767-3. Epub 2011 May 10.
The purpose of this observational study was to evaluate disease-free survival, overall survival, local recurrence rate, and morbidities in patients submitted to class III nerve-sparing radical hysterectomy (NSRH) compared with standard radical hysterectomy (RH) in cervical cancer (CC). This was a comparative study in the context of multimodal therapies.
We investigated patients with CC admitted to the National Cancer Institute of Milan between January 4, 2001, and September 29, 2009, treated with NSRH. We compared patients operated with RH between March 20, 1980, and December 28, 1995. A total of 496 patients were enrolled. The median follow-up was 93 months (42 and 159 months for the NSRH and RH groups, respectively).
The overall number of relapses was 30 out of 185 and 60 out of 311 for NSRH and RH, respectively. Five-year disease-free survival estimate was 78.9% (95% confidence interval [CI] 72.0-85.7) in NSRH and 79.8% (95% CI 75.3-84.3) in RH (P=0.519). Five-year overall survival estimate was 90.8% (95% CI 85.9-95.6) in NSRH and 84.1% (95% CI 8.0-88.3) in RH (P=0.192). Rates of postoperative serious complications were 9.7% and 19.6% for NSRH and RH, respectively (P=0.004). Positive pelvic lymph node and vagina status were significant (P<0.01) independent predictors by multivariable analyses.
The oncologic results were comparable between NSRH and conventional class III RH in the context of two multimodal treatments. Bladder function and postoperative complications rate are improved by nerve-sparing technique. The nerve-sparing technique should be considered in all CC patients addressed to surgery because it improves functional outcome and preserves radicality without compromising overall survival.
本观察性研究旨在评估与标准根治性子宫切除术(RH)相比,接受 III 级神经保留根治性子宫切除术(NSRH)的宫颈癌(CC)患者的无病生存率、总生存率、局部复发率和发病率。这是多模式治疗背景下的一项比较研究。
我们调查了 2001 年 1 月 4 日至 2009 年 9 月 29 日期间在米兰国家癌症研究所接受 NSRH 治疗的 CC 患者,并将其与 1980 年 3 月 20 日至 1995 年 12 月 28 日期间接受 RH 治疗的患者进行了比较。共有 496 名患者入组。中位随访时间为 93 个月(NSRH 组和 RH 组分别为 42 个月和 159 个月)。
NSRH 组和 RH 组的总复发数分别为 30 例和 60 例。NSRH 的 5 年无病生存率估计值为 78.9%(95%置信区间[CI]72.0-85.7),RH 为 79.8%(95% CI 75.3-84.3)(P=0.519)。NSRH 的 5 年总生存率估计值为 90.8%(95% CI 85.9-95.6),RH 为 84.1%(95% CI 8.0-88.3)(P=0.192)。NSRH 和 RH 的术后严重并发症发生率分别为 9.7%和 19.6%(P=0.004)。多变量分析显示,盆腔淋巴结和阴道阳性是显著的(P<0.01)独立预测因素。
在两种多模式治疗的背景下,NSRH 与传统的 III 级 RH 的肿瘤学结果相当。神经保留技术可改善膀胱功能和术后并发症发生率。对于接受手术治疗的所有 CC 患者,都应考虑神经保留技术,因为它可以改善功能预后,在不影响总生存率的情况下保留根治性。